ArticleMedicine2025
Mendelian randomization analysis of lipid-lowering drug targets and neuropsychiatric disorders.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid-lowering therapies are widely prescribed, but their potential neuropsychiatric consequences remain incompletely understood. Clarification of these associations is clinically important given the global burden of mental disorders and the widespread use of these agents. Genetic variants within asialoglycoprotein receptor 1, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, proprotein convertase subtilisin/kexin type 9, and Niemann-Pick C1-like 1 were selected from genome-wide association study data and used as instruments in drug-target Mendelian randomization analyses. Six neuropsychiatric outcomes-suicide attempt, depression, anxiety, schizophrenia, seizures, and insomnia-were evaluated. Familial hyperlipidemia was analyzed as a positive control. Causal estimates were obtained using inverse variance weighting and weighted median methods, while sensitivity and co-localization analyses were performed to test robustness. Genetic proxies for all 4 drug targets were found to be strongly associated with reduced risk of familial hyperlipidemia, supporting instrument validity. Asialoglycoprotein receptor 1 inhibition was associated with a lower risk of depression (odds ratio [OR] = 0.28, 95% confidence interval [CI] = 0.11-0.72, P = .008). 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibition was associated with reduced risks of suicide attempt (OR = 0.82, 95% CI = 0.68-0.99, P = .038) and schizophrenia (OR = 0.53, 95% CI = 0.31-0.89, P = .017). Niemann-Pick C1-like 1 inhibition was inversely associated with schizophrenia (OR = 0.31, 95% CI = 0.11-0.93, P = .037). In contrast, proprotein convertase subtilisin/kexin type 9 inhibition was associated with an increased risk of epilepsy (OR = 1.46, 95% CI = 0.18-0.81, P < .001). These findings suggest that lipid-lowering drug targets may exert heterogeneous effects on neuropsychiatric outcomes. Target-specific associations might point to biological pathways linking lipid metabolism and brain health, but the results should be considered exploratory. Further translational and clinical studies are required to validate and clarify their implications for patient care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.